MichaelHTomassonMD
Hematology • Iowa City, IAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Associate Professor, Internal Medicine, Washington University School of Medicine
Dr. Tomasson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Dept of Internal Medicine
Iowa City, IA 52242Phone+1 319-335-4958Fax+1 314-454-7551
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1994
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1993 - Present
IA State Medical License 2016 - 2025
MO State Medical License 2000 - 2017
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
- Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
- Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
- Join now to see all
Publications & Presentations
PubMed
- Cardiovascular function and autonomic regulation in urethane-anesthetized and conscious mice.Anastasiia Vasileva, Laura D M Flores, Mikhail Vasilyev, Michelle A Buckman, Lara R DeRuisseau
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2025-01-01 - Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.Breanna B Greteman, Michael H Tomasson, Amanda R Kahl, Madison M Wahlen, Melissa L Bates
Cancer Causes & Control. 2024-11-26 - 1 citationsLong-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.Michael H Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis
Hemasphere. 2024-07-01
Lectures
- A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety a...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Nanotherapy Effective in Mice with Multiple MyelomaMay 21st, 2015
Grant Support
- Genomics Of AML: Contribution Of Cytokine Signaling Pathways To LeukemogenesisNational Cancer Institute2008–2012
- Environment &Genetics Of Monoclonal Gammopathy Of Uncertain Significance (MGUS)National Institute On Aging2011
- Exploration Of Neurobeachin (Nbea)'S Role In Multiple MyelomaNational Cancer Institute2009–2010
- Genetic Progression Factors In Multiple Myeloma And MGUSNational Cancer Institute2006
- Molecular Analysis Of Transformation In Tel/Pdgfr MiceNational Cancer Institute2000–2003
- Molecular Analysis Of Transformation In Tel/Pdgfr MiceNational Cancer Institute1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
